Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program

BACKGROUND: High-dose interleukin-2 (IL-2) has been FDA-approved for over 20 years, but it is offered only at a small number of centers with expertise in its administration. We analyzed the outcomes of patients receiving high-dose IL-2 in relation to the severity of toxicity to ascertain if response...

Descripción completa

Detalles Bibliográficos
Autores principales: Payne, Roxanne, Glenn, Lyn, Hoen, Helena, Richards, Beverley, Smith, John W, Lufkin, Robert, Crocenzi, Todd S, Urba, Walter J, Curti, Brendan D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030280/
https://www.ncbi.nlm.nih.gov/pubmed/24855563
http://dx.doi.org/10.1186/2051-1426-2-13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030280/
https://www.ncbi.nlm.nih.gov/pubmed/24855563
http://dx.doi.org/10.1186/2051-1426-2-13

Ejemplares similares